FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Alpelisib | Breast Cancer | PHASE3 | ACTIVE_NOT_RECRUITING |
| Arm A: Gedatolisib + Palbociclib + Fulve | Breast Cancer | PHASE3 | RECRUITING |
| Arm B: Ribociclib + Fulvestrant | Breast Cancer | PHASE3 | RECRUITING |
| Arm C: Gedatolisib + Palbociclib + Letro | Breast Cancer | PHASE3 | RECRUITING |
| Arm D: Ribociclib + Letrozole | Breast Cancer | PHASE3 | RECRUITING |
| Palbociclib | Breast Cancer | PHASE3 | ACTIVE_NOT_RECRUITING |
| Gedatolisib | Breast Cancer | PHASE3 | ACTIVE_NOT_RECRUITING |
| Weekly Paclitaxel | HER2-negative Breast Cancer | PHASE2 | UNKNOWN |
| Abemaciclib | Endometrial Cancer | PHASE2 | RECRUITING |
| Trastuzumab | HER2-negative Breast Cancer | PHASE2 | UNKNOWN |
CELC holds $182M in cash and burns about $55.2M/quarter from operations, giving an estimated runway of 9.9 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for CELC free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-07-16 | BAKER BROS. ADVISORS LP |
Sale | $45.4M |
| 2026-07-16 | BAKER BROS. ADVISORS LP |
Sale | $448.2M |
| 2026-06-12 | Buller Richard E |
Sale | $0 |
| 2026-06-12 | Buller Richard E |
Purchase | $0 |
| 2026-06-12 | Murphy Polly A. |
Sale | $0 |
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-07-17 | — | NDA | +0.1% | +0.1% | — |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for CELC and 2 more tickers of your choice.
Create Free Account →